Shares of Neurogene Inc. (NASDAQ:NGNE – Get Free Report) have been assigned an average rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $51.00.
NGNE has been the topic of several recent research reports. BMO Capital Markets assumed coverage on shares of Neurogene in a report on Thursday, June 27th. They issued an “outperform” rating and a $65.00 price objective on the stock. Baird R W raised Neurogene to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird started coverage on Neurogene in a research note on Tuesday, June 11th. They set an “outperform” rating and a $54.00 price objective for the company. Finally, HC Wainwright lowered their target price on Neurogene from $51.00 to $49.00 and set a “buy” rating on the stock in a research note on Monday, August 12th.
View Our Latest Stock Analysis on NGNE
Institutional Investors Weigh In On Neurogene
Neurogene Stock Up 1.8 %
Shares of NGNE opened at $35.00 on Tuesday. The stock has a 50-day moving average of $38.20 and a two-hundred day moving average of $36.98. Neurogene has a one year low of $12.49 and a one year high of $53.00.
Neurogene (NASDAQ:NGNE – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.07). The company had revenue of $0.93 million during the quarter. On average, equities analysts expect that Neurogene will post -4.47 earnings per share for the current year.
Neurogene Company Profile
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Recommended Stories
- Five stocks we like better than Neurogene
- How to Use the MarketBeat Excel Dividend Calculator
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Conference Calls and Individual Investors
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- 5 discounted opportunities for dividend growth investors
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.